BACKGROUND: Although contralateral prophylactic mastectomy (CPM) reduced the risk of contralateral breast cancer in unilateral breast cancer patients, it was difficult to predict which patients were most likely to benefit from the procedure. The objective of this study was to identify the clinicopathologic factors that predict contralateral breast cancer and thereby inform decisions regarding performing CPM in unilateral breast cancer patients. METHODS: A total of 542 unilateral breast cancer patients who underwent CPM at The University of Texas M. D. Anderson Cancer Center from January 2000 to April 2007 were included in the current study. A logistic regression analysis was used to identify clinicopathologic factors that predict contralateral breast cancer. RESULTS: Of the 542 patients included in this study, 25 (5%) had an occult malignancy in the contralateral breast. Eighty-two patients (15%) had moderate-risk to high-risk histologic findings identified at final pathologic evaluation of the contralateral breast. Multivariate analysis revealed that 3 independent factors predicted malignancy in the contralateral breast: an ipsilateral invasive lobular histology, an ipsilateral multicentric tumor, and a 5-year Gail risk >or=1.67%. Multivariate analysis also revealed that an age >or=50 years at the time of the initial cancer diagnosis and an additional ipsilateral moderate-risk to high-risk pathology were independent predictors of moderate-risk to high-risk histologic findings in the contralateral breast. CONCLUSIONS: The findings indicated that CPM may be a rational choice for breast cancer patients who have a 5-year Gail risk >or=1.67%, an additional ipsilateral moderate-risk to high-risk pathology, an ipsilateral multicentric tumor, or an ipsilateral tumor of invasive lobular histology. (c) 2009 American Cancer Society.
BACKGROUND: Although contralateral prophylactic mastectomy (CPM) reduced the risk of contralateral breast cancer in unilateral breast cancerpatients, it was difficult to predict which patients were most likely to benefit from the procedure. The objective of this study was to identify the clinicopathologic factors that predict contralateral breast cancer and thereby inform decisions regarding performing CPM in unilateral breast cancerpatients. METHODS: A total of 542 unilateral breast cancerpatients who underwent CPM at The University of Texas M. D. Anderson Cancer Center from January 2000 to April 2007 were included in the current study. A logistic regression analysis was used to identify clinicopathologic factors that predict contralateral breast cancer. RESULTS: Of the 542 patients included in this study, 25 (5%) had an occult malignancy in the contralateral breast. Eighty-two patients (15%) had moderate-risk to high-risk histologic findings identified at final pathologic evaluation of the contralateral breast. Multivariate analysis revealed that 3 independent factors predicted malignancy in the contralateral breast: an ipsilateral invasive lobular histology, an ipsilateral multicentric tumor, and a 5-year Gail risk >or=1.67%. Multivariate analysis also revealed that an age >or=50 years at the time of the initial cancer diagnosis and an additional ipsilateral moderate-risk to high-risk pathology were independent predictors of moderate-risk to high-risk histologic findings in the contralateral breast. CONCLUSIONS: The findings indicated that CPM may be a rational choice for breast cancerpatients who have a 5-year Gail risk >or=1.67%, an additional ipsilateral moderate-risk to high-risk pathology, an ipsilateral multicentric tumor, or an ipsilateral tumor of invasive lobular histology. (c) 2009 American Cancer Society.
Authors: A M Shaaban; J P Sloane; C R West; F R Moore; C Jarvis; E M I Williams; C S Foster Journal: Am J Surg Pathol Date: 2002-04 Impact factor: 6.394
Authors: Judy C Boughey; Nazanin Khakpour; Funda Meric-Bernstam; Merrick I Ross; Henry M Kuerer; Sonja E Singletary; Gildy V Babiera; Banu Arun; Kelly K Hunt; Isabelle Bedrosian Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: L A Newman; A A Sahin; J E Cunningham; M L Bondy; N Q Mirza; G S Vlastos; G J Whitman; H Brown; T A Buchholz; M H Lee; S E Singletary Journal: Cancer Date: 2001-05-15 Impact factor: 6.860
Authors: David L Page; Peggy A Schuyler; William D Dupont; Roy A Jensen; W Dale Plummer; Jean F Simpson Journal: Lancet Date: 2003-01-11 Impact factor: 79.321
Authors: Katja Goldflam; Kelly K Hunt; Jeffrey E Gershenwald; S Eva Singletary; Nadeem Mirza; Henry M Kuerer; Gildy V Babiera; Frederick C Ames; Merrick I Ross; Barry W Feig; Aysegul A Sahin; Banu Arun; Funda Meric-Bernstam Journal: Cancer Date: 2004-11-01 Impact factor: 6.860
Authors: L E Rutqvist; B Cedermark; U Glas; A Mattsson; L Skoog; A Somell; T Theve; N Wilking; J Askergren; M L Hjalmar Journal: J Natl Cancer Inst Date: 1991-09-18 Impact factor: 13.506
Authors: Constance D Lehman; Constantine Gatsonis; Christiane K Kuhl; R Edward Hendrick; Etta D Pisano; Lucy Hanna; Sue Peacock; Stanley F Smazal; Daniel D Maki; Thomas B Julian; Elizabeth R DePeri; David A Bluemke; Mitchell D Schnall Journal: N Engl J Med Date: 2007-03-28 Impact factor: 91.245
Authors: J E Gershenwald; K K Hunt; S S Kroll; M I Ross; B J Baldwin; B W Feig; F C Ames; M A Schusterman; S E Singletary Journal: Ann Surg Oncol Date: 1998-09 Impact factor: 5.344
Authors: Min Yi; Kelly K Hunt; Banu K Arun; Isabelle Bedrosian; Angelica Gutierrez Barrera; Kim-Anh Do; Henry M Kuerer; Gildy V Babiera; Elizabeth A Mittendorf; Kaylene Ready; Jennifer Litton; Funda Meric-Bernstam Journal: Cancer Prev Res (Phila) Date: 2010-07-20
Authors: Benjamin Zendejas; James P Moriarty; Jamie O'Byrne; Amy C Degnim; David R Farley; Judy C Boughey Journal: J Clin Oncol Date: 2011-06-20 Impact factor: 44.544
Authors: K Graham; A de las Morenas; A Tripathi; C King; M Kavanah; J Mendez; M Stone; J Slama; M Miller; G Antoine; H Willers; P Sebastiani; C L Rosenberg Journal: Br J Cancer Date: 2010-03-02 Impact factor: 7.640
Authors: Sheenu Chandwani; Prethibha A George; Michelle Azu; Elisa V Bandera; Christine B Ambrosone; George G Rhoads; Kitaw Demissie Journal: Ann Surg Oncol Date: 2014-06-10 Impact factor: 5.344